Baidu
map

Carcinogenesis:TAZ诱导乳腺癌机制被破解

2012-01-06 MedSci原创 MedSci原创

近日,国际癌症领域主流杂志Carcinogenesis刊登了中国科学院昆明动物研究所研究人员的最新研究成果“TAZ antagonizes the WWP1-mediated KLF5 degradation and promotes breast cell proliferation and tumorigenesis。”文章中,研究人员首次证实了TAZ促进乳腺细胞的增生机制是部分通过保护KLF

近日,国际癌症领域主流杂志Carcinogenesis刊登了中国科学院昆明动物研究所研究人员的最新研究成果“TAZ antagonizes the WWP1-mediated KLF5 degradation and promotes breast cell proliferation and tumorigenesis。”文章中,研究人员首次证实了TAZ促进乳腺细胞的增生机制是部分通过保护KLF5免受WWP1介导的泛素化降解。

乳腺癌是女性最常见的恶性肿瘤之一,雌激素受体ER、孕激素受体PR和表皮生长因子受体HER2均为阴性的(简称三阴性)乳腺癌是预后最差的一类,目前没有有效的靶向治疗药物,对放射治疗和化疗也不敏感,因此寻找三阴性乳腺癌的有效治疗靶点是目前研究的热点之一。中国科学院昆明动物研究所肿瘤生物学实验室陈策实研究员领导的学科组前期研究显示KLF5转录因子在一部分三阴性的乳腺癌中特异高表达,KLF5通过紧密控制FGF-BP癌基因表达促进细胞增殖、生存以及肿瘤生长,WWP1 E3泛素连接酶促进KLF5蛋白的降解并抑制其功能,但是KLF5的正向调控机制尚不清楚。

最近,中国科学院昆明动物研究所肿瘤生物学实验室陈策实研究员博士后赵东等人,通过一系列实验研究发现, Hippo肿瘤抑制信号途径的TAZ(transcriptional co-activator with a PDZ-binding motif)癌蛋白通过其WW结构域结合KLF5的PPXY序列,拮抗WWP1 介导的KLF5的蛋白降解,促进KLF5的下游基因表达、细胞增殖以及肿瘤生长。而抑制TAZ的蛋白激酶LATS1可以通过TAZ抑制KLF5的表达和活性。这项研究首次证实了TAZ促进乳腺细胞的增生机制是部分通过保护KLF5免受WWP1介导的泛素化降解,从而增强KLF5对下游癌基因表达的控制并且促进细胞周期进展。该研究提示KLF5可能是Hippo肿瘤抑制信号途径中的关键下游成员,并且证明KLF5和TAZ可以作为三阴性乳腺癌的潜在治疗靶点。

该项研究得到了国家自然科学基金和云南省高端人才项目支持。(生物谷Bioon.com)

TAZ antagonizes the WWP1-mediated KLF5 degradation and promotes breast cell proliferation and tumorigenesis

Dong Zhao1,2,†, Xu Zhi1,2,†, Zhongmei Zhou1 and Ceshi Chen1,*

Krüppel-like factor 5 (KLF5) is a PY motif-containing transcription factor promoting breast cell proliferation. The KLF5 protein is rapidly degraded through the proteasome after ubiquitination by E3 ubiquitin ligases, such as WWP1 and SCFFbw7. In this study, we demonstrated that a transcriptional co-activator with the PDZ binding motif (TAZ) upregulated the KLF5 expression through antagonizing the WWP1-, but not Fbw7-, mediated, KLF5 ubiquitination and degradation. TAZ interacted with KLF5 through the WW domain of TAZ and the PY motif of KLF5, which is the binding site for WWP1. TAZ inhibited WWP1-KLF5 protein interaction and WWP1-mediated KLF5 ubiquitination and degradation in a WW domain dependent manner. Overexpression of TAZ up-regulated the protein levels of KLF5 and FGF-BP, which is a well established KLF5 target gene. In addition, depletion of TAZ in both 184A1 and HCC1937 breast cells down-regulated protein levels of KLF5 and FGF-BP and inhibited cell growth. Furthermore, stable depletion of either TAZ or KLF5 significantly suppressed HCC1937 xenograft growth in immunodeficient mice. Knockdown of LATS1, a TAZ upstream inhibitory kinase, up-regulated the protein levels of KLF5 and FGF-BP in 184A1 and promoted cell growth through TAZ. Finally, both KLF5 and TAZ were co-expressed in a subset of estrogen receptor (ERα)-negative breast cell lines. These results, for the first time, suggest that TAZ promotes breast cell growth partially through protecting KLF5 from WWP1-mediated degradation and enhancing KLF5’s activities.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1714690, encodeId=17471e14690ab, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3073, encryptionId=021230e312, topicName=AZ)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e5031899089, createdName=12498e5fm22(暂无昵称), createdTime=Fri Dec 07 10:26:00 CST 2012, time=2012-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773423, encodeId=13511e734231a, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Thu Nov 01 18:26:00 CST 2012, time=2012-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024439, encodeId=3e0c2024439c5, content=<a href='/topic/show?id=b10640893f' target=_blank style='color:#2F92EE;'>#Carcinogenesis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4089, encryptionId=b10640893f, topicName=Carcinogenesis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Tue Jan 10 02:26:00 CST 2012, time=2012-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048414, encodeId=f19120484141b, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sun Sep 16 21:26:00 CST 2012, time=2012-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1588136, encodeId=34b215881365a, content=<a href='/topic/show?id=1cb8e014e0' target=_blank style='color:#2F92EE;'>#ESI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7014, encryptionId=1cb8e014e0, topicName=ESI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4f817593223, createdName=skhzy, createdTime=Sun Jan 08 14:26:00 CST 2012, time=2012-01-08, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1714690, encodeId=17471e14690ab, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3073, encryptionId=021230e312, topicName=AZ)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e5031899089, createdName=12498e5fm22(暂无昵称), createdTime=Fri Dec 07 10:26:00 CST 2012, time=2012-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773423, encodeId=13511e734231a, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Thu Nov 01 18:26:00 CST 2012, time=2012-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024439, encodeId=3e0c2024439c5, content=<a href='/topic/show?id=b10640893f' target=_blank style='color:#2F92EE;'>#Carcinogenesis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4089, encryptionId=b10640893f, topicName=Carcinogenesis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Tue Jan 10 02:26:00 CST 2012, time=2012-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048414, encodeId=f19120484141b, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sun Sep 16 21:26:00 CST 2012, time=2012-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1588136, encodeId=34b215881365a, content=<a href='/topic/show?id=1cb8e014e0' target=_blank style='color:#2F92EE;'>#ESI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7014, encryptionId=1cb8e014e0, topicName=ESI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4f817593223, createdName=skhzy, createdTime=Sun Jan 08 14:26:00 CST 2012, time=2012-01-08, status=1, ipAttribution=)]
    2012-11-01 kalseyzl
  3. [GetPortalCommentsPageByObjectIdResponse(id=1714690, encodeId=17471e14690ab, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3073, encryptionId=021230e312, topicName=AZ)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e5031899089, createdName=12498e5fm22(暂无昵称), createdTime=Fri Dec 07 10:26:00 CST 2012, time=2012-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773423, encodeId=13511e734231a, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Thu Nov 01 18:26:00 CST 2012, time=2012-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024439, encodeId=3e0c2024439c5, content=<a href='/topic/show?id=b10640893f' target=_blank style='color:#2F92EE;'>#Carcinogenesis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4089, encryptionId=b10640893f, topicName=Carcinogenesis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Tue Jan 10 02:26:00 CST 2012, time=2012-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048414, encodeId=f19120484141b, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sun Sep 16 21:26:00 CST 2012, time=2012-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1588136, encodeId=34b215881365a, content=<a href='/topic/show?id=1cb8e014e0' target=_blank style='color:#2F92EE;'>#ESI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7014, encryptionId=1cb8e014e0, topicName=ESI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4f817593223, createdName=skhzy, createdTime=Sun Jan 08 14:26:00 CST 2012, time=2012-01-08, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1714690, encodeId=17471e14690ab, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3073, encryptionId=021230e312, topicName=AZ)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e5031899089, createdName=12498e5fm22(暂无昵称), createdTime=Fri Dec 07 10:26:00 CST 2012, time=2012-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773423, encodeId=13511e734231a, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Thu Nov 01 18:26:00 CST 2012, time=2012-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024439, encodeId=3e0c2024439c5, content=<a href='/topic/show?id=b10640893f' target=_blank style='color:#2F92EE;'>#Carcinogenesis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4089, encryptionId=b10640893f, topicName=Carcinogenesis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Tue Jan 10 02:26:00 CST 2012, time=2012-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048414, encodeId=f19120484141b, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sun Sep 16 21:26:00 CST 2012, time=2012-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1588136, encodeId=34b215881365a, content=<a href='/topic/show?id=1cb8e014e0' target=_blank style='color:#2F92EE;'>#ESI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7014, encryptionId=1cb8e014e0, topicName=ESI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4f817593223, createdName=skhzy, createdTime=Sun Jan 08 14:26:00 CST 2012, time=2012-01-08, status=1, ipAttribution=)]
    2012-09-16 cy0324
  5. [GetPortalCommentsPageByObjectIdResponse(id=1714690, encodeId=17471e14690ab, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3073, encryptionId=021230e312, topicName=AZ)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e5031899089, createdName=12498e5fm22(暂无昵称), createdTime=Fri Dec 07 10:26:00 CST 2012, time=2012-12-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773423, encodeId=13511e734231a, content=<a href='/topic/show?id=5f014e1852' target=_blank style='color:#2F92EE;'>#CIN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4718, encryptionId=5f014e1852, topicName=CIN)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9a038523631, createdName=kalseyzl, createdTime=Thu Nov 01 18:26:00 CST 2012, time=2012-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024439, encodeId=3e0c2024439c5, content=<a href='/topic/show?id=b10640893f' target=_blank style='color:#2F92EE;'>#Carcinogenesis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4089, encryptionId=b10640893f, topicName=Carcinogenesis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Tue Jan 10 02:26:00 CST 2012, time=2012-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048414, encodeId=f19120484141b, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sun Sep 16 21:26:00 CST 2012, time=2012-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1588136, encodeId=34b215881365a, content=<a href='/topic/show?id=1cb8e014e0' target=_blank style='color:#2F92EE;'>#ESI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7014, encryptionId=1cb8e014e0, topicName=ESI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4f817593223, createdName=skhzy, createdTime=Sun Jan 08 14:26:00 CST 2012, time=2012-01-08, status=1, ipAttribution=)]
    2012-01-08 skhzy

相关资讯

NEJM:贝伐单抗提高攻击性乳腺癌患者生存期

美国FDA于11月份取消了安维汀(贝伐单抗)用于治疗乳腺癌的适应证,但是最近一项新的研究表明,当与其他两种药物联合使用时,安维汀有利于提高攻击性乳腺癌患者的生存期。 这项新的研究由基因泰克公司发起。研究人员评估了该药在HER2阳性乳腺癌的治疗效果,HER2阳性乳腺癌通常对标准激素治疗不敏感而且比其他类型的乳腺癌更具有攻击性和转移性。 一共有216名患者接受了安维汀与曲妥珠单抗(赫赛汀)以及

靶向治疗和乳腺癌疫苗(斯坦福大学公开课)

靶向治疗和乳腺癌疫苗(斯坦福大学公开课)

J Pathol.:乳腺癌基因BRCA1有助治疗间皮瘤

恶性胸膜间皮瘤是肺和胸壁之间的癌症。它一般是由接触石棉引起,尽管罕见,全球的病例数却在不断增加,尽管有些病人对抗有丝分裂的化疗药物长春瑞滨(Vinorelbine)有响应,恶性胸膜间皮瘤的治疗方法依然相当有限。爱尔兰研究人员发现乳腺癌基因BRCA1的变化与恶性胸膜间皮瘤有关。 这项研究的成果发表在《病理学期刊》上,研究人员观察了144例间皮瘤样本,发现近40%没有表达BRCA1蛋白,这与对长

JCO:放疗增加乳腺癌患者发生冠脉狭窄的风险

(图片来源:Medpage Today) 瑞典乌普萨拉大学的Greger Nilsson博士等近日在《临床肿瘤学杂志》(Journal of Clinical Oncology)发表论文称,接受乳腺癌放射治疗的患者,其暴露区域的冠状动脉更易发生狭窄或堵塞。 作者称,接受放疗的左侧乳腺癌患者,其暴露区域的冠状动脉中远段和左前降支的对角支远端发生狭窄和堵塞的风险显着高于右侧乳腺癌患者。放疗被认为可

PNAS:阎锡蕴等揭示CD146分子促进乳腺癌进展新机制

近日,国际著名杂志《美国国家科学院院刊》PNAS在线发表中国科学院生物物理研究所阎锡蕴课题组的最新研究成果“CD146, a epithelial-mesenchymal transition inducer, is associated with triple-negative breast cancer。”,文章中,该项研究首次报道细胞黏附分子CD146促进乳腺癌进展的新机制。 阎锡蕴课

JCI:鉴定出阻止乳腺癌扩散的新靶标

一个延缓乳腺癌进展与转移的新潜在靶标已由一个研究小组鉴定出来,该研究小组由来自麦克吉尔大学健康中心研究所(RI-MUHC)的Richard Kremer博士所领导。乳腺癌患者并发症通常是因为疾病转移向身体其他部分的扩散所导致的,最常见的是转移向骨髓和肺。 这些发现发表在《临床调查研究杂志》(JCI)上,提出一个特异蛋白在此疾病原发肿瘤区域外的进展发挥关键作用。 研究人员指出,这个被称为甲状旁腺

Baidu
map
Baidu
map
Baidu
map